Comparative search between HIV medicines in Covid-19

Randomized double-blind clinical trial comparing Atazanavir + Ritonavir + Doxycycline versus Atazanavir + Ritonavir in patients with laboratory or clinical diagnosis for Covid-19, in the state of Pernambuco and Alagoas – Brazil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-6wgwxsy

Enrollment

Unknown

Registered

2022-03-14

Start date

2022-04-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Arm 1 (intervention - 318 individuals): Atazanavir 300mg 1 tablet + Ritonavir 100mg 1 tablet + Doxycycline 100mg 1 tablet - orally once a day during 10 days Arm 2 (intervention - 318 individuals)

D27.505.954.122.388.077

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: outpacients with positive diagnosis for COVID-19

Exclusion criteria

Exclusion criteria: Patients with indication for hospital admission; patients with other protease inhibitors; pregnant; infants; more than 5 days from the onset of symptoms, HIV positive patients

Design outcomes

Primary

Measure	Time frame
To evaluate the number of hospitalizations, verified by the percentage of hospitalization of the experimental and control groups, based on a finding of a variation of at least 5% in pre- and post-intervention measurements.;To evaluate hospital discharge rate, verified by the percentage of discharge rate of the experimental and control groups, based on a finding of a variation of at least 5% in pre- and post-intervention measurements.;To evaluate hospital death rate, verified by the percentage of death rate of the experimental and control groups, based on a finding of a variation of at least 5% in pre- and post-intervention measurements.	—

Measure

Time frame

To evaluate the number of hospitalizations, verified by the percentage of hospitalization of the experimental and control groups, based on a finding of a variation of at least 5% in pre- and post-intervention measurements.;To evaluate hospital discharge rate, verified by the percentage of discharge rate of the experimental and control groups, based on a finding of a variation of at least 5% in pre- and post-intervention measurements.;To evaluate hospital death rate, verified by the percentage of death rate of the experimental and control groups, based on a finding of a variation of at least 5% in pre- and post-intervention measurements.

—

Secondary

Measure	Time frame
No secundary outcome expected	—

Countries

Brazil

Contacts

Public ContactEvônio Campelo

Universidade Federal de Pernambuco

evoniocampelo55@gmail.com55(81)999254455

Outcome results

None listed

Source: REBEC (via WHO ICTRP)